Palvella Therapeutics (PVLA) Current Deferred Revenue (2013 - 2023)

Palvella Therapeutics (PVLA) has 9 years of Current Deferred Revenue data on file, last reported at $3.5 million in Q3 2023.

• Quarterly Current Deferred Revenue rose 400.0% year-over-year to $3.5 million in Q3 2023, while the trailing twelve-month figure through Sep 2023 was $3.5 million (up 400.0% YoY) and the FY2022 annual result came in at $20.8 million, down 17.09% from the prior year.
• Current Deferred Revenue fell to $3.5 million in Q3 2023 per PVLA's latest filing, from $4.7 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $28.4 million in Q2 2019 and bottomed at $700000.0 in Q3 2022.
• The 5-year median for Current Deferred Revenue is $20.8 million (2022), against an average of $17.4 million.
• The widest annual swing landed in 2022, when Current Deferred Revenue slumped 97.35%; it then soared 400.0% in 2023.
• Tracing PVLA's Current Deferred Revenue over 5 years: stood at $11.3 million in 2019, then gained by 12.18% to $12.6 million in 2020, then surged by 98.91% to $25.1 million in 2021, then decreased by 17.09% to $20.8 million in 2022, then slumped by 83.19% to $3.5 million in 2023.
• Per Business Quant, the three latest PVLA Current Deferred Revenue figures stand at $3.5 million (Q3 2023), $4.7 million (Q2 2023), and $26.7 million (Q1 2023).

Peer Comparison